Transcriptomic Biomarkers for Heart Failure Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting and diagnosing heart diseases lack accuracy, leading to inadequate risk assessment and prognosis, particularly in newly diagnosed patients, resulting in inappropriate therapy allocation and patient management.
Innovation Solution
The use of transcriptomic biomarkers, specifically a molecular signature comprising nucleic acid sequences such as Hypoxia inducible factor 3, Epidermal growth factor receptor pathway substrate 15-like 1, and others, to identify and differentiate between patients at high risk of heart disease and those with a good prognosis through expression profiling in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard prediction tools based on conventional criteria are used, then the assessment process is simple and easy to implement, but the accuracy of risk assessment and prognosis prediction is limited
Solution Approach 1:
The patent transforms the assessment from conventional clinical parameters to molecular expression levels. By measuring the expression levels of specific genes (e.g., HIF3A, EGFR pathway substrate 15-like 1) in biological samples, the system achieves higher diagnostic accuracy. This parameter transformation enables precise identification of patients at high risk for heart failure progression, directly resolving the contradiction between accuracy and complexity by operating at the molecular level rather than relying on complex multi-parameter clinical evaluation.
Solution Approach 2:
The patent extracts specific molecular biomarkers from complex biological systems to create a focused diagnostic approach. By identifying and measuring particular gene expressions that are differentially expressed in heart failure patients, the method isolates key predictive indicators from the complexity of overall disease pathology. This extraction principle allows accurate risk stratification while simplifying the assessment to specific molecular measurements rather than comprehensive clinical evaluation.
2Reliability
If transcriptomic biomarkers are used for accurate prognosis prediction, then the diagnostic accuracy is improved, but the complexity of the assessment method increases
Solution Approach 1:
The patent segments the complex task of heart failure prognosis into discrete molecular measurements. By focusing on specific gene expression levels (such as HIF3A and EGFR pathway substrate 15-like 1) rather than attempting to analyze the entire transcriptome, the method achieves reliable prediction while managing complexity through targeted measurement. This segmentation allows the use of standardized molecular assays that can be integrated into existing diagnostic workflows.
Solution Approach 2:
The patent introduces molecular biomarkers as intermediaries between the complex biological disease process and the diagnostic assessment. These specific gene expressions serve as measurable intermediaries that reflect underlying pathological processes without requiring direct observation of complex disease mechanisms. This intermediary approach enables reliable prognosis prediction through standardized molecular measurements while avoiding the need for complex systems-level analysis.
3Measurement precision
If molecular signatures are analyzed to distinguish high-risk patients, then the precision of patient classification is improved, but the difficulty of detection and measurement increases
Solution Approach 1:
The patent measures gene expression levels as quantitative parameters that directly indicate patient risk classification. By converting molecular presence/absence into measurable expression levels (e.g., relative expression compared to control samples), the method achieves precise patient stratification. This parameter measurement approach uses established molecular biology techniques that can quantify gene expression, transforming the detection task into a standardized measurement process with clear interpretative thresholds.
Data Source
AI summary
A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.